Hematopoietic stem cell transplantation from non-sibling matched family donors for patients with thalassemia major in Jordan

There are limited data on the outcome of patients with thalassemia receiving HSCT from non‐sibling matched family donors. Of the 341 patients with thalassemia major that underwent donor search at our center from January 2003 to December 2011, 236 (69.2%) had fully matched family donor of which 28 pa...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric transplantation 2016-02, Vol.20 (1), p.120-123
Main Authors: Hussein, Ayad Ahmed, Al-Zaben, Abdulhadi, Khattab, Eman, Haroun, Anas, Frangoul, Haydar
Format: Article
Language:English
Subjects:
Adolescent
Adult
beta-Thalassemia - genetics
beta-Thalassemia - therapy
Blood Platelets - cytology
Child
Child, Preschool
Family
Female
Genotype
hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - methods
Histocompatibility Testing
HLA Antigens - immunology
Humans
Jordan
Male
Middle Aged
Neutrophils - cytology
non-sibling donor
Retrospective Studies
thalassemia
Tissue Donors
Transplantation Conditioning
Treatment Outcome
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are limited data on the outcome of patients with thalassemia receiving HSCT from non‐sibling matched family donors. Of the 341 patients with thalassemia major that underwent donor search at our center from January 2003 to December 2011, 236 (69.2%) had fully matched family donor of which 28 patients (8.2%) had non‐sibling matched family donors identified. We report on seven patients with a median age of eight yr (4–21) who underwent myeloablative (n = 4) or RIC (n = 3) HSCT. The median age of the donors was 33 yr (4–47), three were parents, two first cousins, one paternal uncle, and one paternal aunt. All patients achieved primary neutrophil and platelet engraftment at a median of 18 (13–20) and 16 days (11–20), respectively. One patient developed grade II acute GVHD, and two patients developed limited chronic GVHD. One patient experienced secondary GF requiring a second transplant. At a median follow‐up of 69 months (7–110), all patients are alive and thalassemia free. Our data emphasize the need for extended family HLA typing for patients with thalassemia major in regions where there is high rate of consanguinity. Transplant from non‐sibling matched family donor can result in excellent outcome.
ISSN:1397-3142
1399-3046
DOI:10.1111/petr.12622